Skip To Main Content
Matteo Barcella on Muck Rack

Matteo Barcella

As seen in: Nature, Science Magazine, Cell Reports Medicine, Cell Stem Cell
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Matteo

Contact Matteo, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Tumor-targeted interferon-α gene therapy for glioblastoma: a phase 1 trial

|
By Bernhard Gentner, Marica Eoli, Francesca Farina, Matteo Barcella, Alessia Capotondo, Antonio Francavilla, Matteo G. Carrabba, Valeria Ferla, Alessandro Bruno, Giorgia Alvisi, Eugenio Montini, Maria Grazia Bruzzone, Francesco Di Meco, Paolo Ferroli, Francesco Acerbi, Roberto Pallini, Quintino Giorgio D’Alessandris, Alessandro Olivi, Filippo Gagliardi, Silvia Snider, Pietro Mortini, Valeria Berno, Pietro Luigi Poliani, Carlo Russo, Fabio Ciceri, Luigi Naldini, Stefania Mazzoleni, Valentina Brambilla, Mariagrazia Garramone, Nadia Coltella, Leila Hadadi, Charlotte Capt, Valeria Cuccarini, Federico G. Legnani, Monica Patanè, Amleto Fiocchi, Gaetano Finocchiaro
| Nature Verified
Abstract Glioblastoma (GBM) is an immunologically cold brain tumor with poor outcome, characterized by a myeloid-driven immunosuppressive microenvironment. Here we report an interim analysis of a first-in-human phase 1/2a dose-escalation study evaluating Temferon—a genetically engineered autologous stem cell transplant designed to deliver interferon-α2 by means of myeloid progeny recruited to the GBM TME and locally activate antitumor immunity.
Open in Who Shared Issue with article?

Nanoengineered 3D culture substrate enables superior persistence and polyclonal engraftment of genetically engineered hematopoietic stem cells

|
By Federico Midena, Laura Alessandrini, Matteo Barcella, Francesco Gazzo, Emanuela Jacchetti, Edoardo Carsana, Roberta Vacca, Lucrezia della Volpe, Sergio Arévalo, Kety Giannetti, Erika Zonari, Francesca Ferrua, Giacomo Farina, Chiara Brombin, Federica Cugnata, Martina Fiumara, Teresa Tavella, Giulio Cerullo, Roberto Osellame, Samuele Ferrari, Ivan Merelli, Bernhard Gentner, Luigi Naldini, Alessandro Aiuti, Eugenio Montini, Raffaella Di Micco, Claudio Conci, Fabrizio Benedicenti, Dafne Barozzi, Martina Franchino, Leonardo Cherubin, Federico Fraschetta, Marina Radrizzani, Cristina Scielzo, Andrea Brendolan, Manuela T. Raimondi
| Cell Stem Cell Verified
STAR★Methods REAGENT or RESOURCESOURCEIDENTIFIER Antibodies Anti-8-oxo-2’deoxyguanosine Trevigen Cat#4354-MC-050; RRID: AB_1857195 Anti-alpha Tubulin antibody – Loading Control Abcam Cat#ab4074; RRID: AB_2288001 Anti-human CD11b PE (Clone M1/70) BioLegend Cat#101207; RRID: AB_312790 Anti-human CD13 BV421 (Clone WM15) BD Biosciences Cat#562596; RRID: AB_2737672 Anti-human CD133/1 PE-Vio 770 (Clone AC133) Miltenyi Biotec Cat#130-113-110; RRID: AB_2725939 Anti-human CD14 APC-Cy7 (Clone M5E2)...
Open in Who Shared Issue with article?

A p38 MAPK-ROS axis fuels proliferation stress and DNA damage during CRISPR-Cas9 gene editing in hematopoietic stem and progenitor cells

|
By Teresa Tavella, Giacomo Farina, Chiara Brandas, Matteo M. Naldini, Matteo Barcella, Samuele Ferrari, Stefano Beretta, Antonella Santoro, Simona Porcellini, Angelica Varesi, Anastasia Conti, Ivan Merelli, Bernhard Gentner, Anna Villa, Luigi Naldini, Raffaella Di Micco, Lucrezia della Volpe, Federico Midena, Roberta Vacca, Laura Alessandrini, Elena Lo Furno, Kety Giannetti, Edoardo Carsana, Diego Gilioli
| Cell Reports Medicine Verified
Keywords hematopoietic stem cells p38 MAPK-ROS gene editing CRISPR-Cas9 DNA damage DNA damage response proliferative stress cell cycle differentiation single-cell analyses clonal output Introduction Ex vivo hematopoietic stem and progenitor cell (HSPC)-based gene therapies (GTs) represent a revolutionary class of “living medicines” for treating various monogenic diseases, including immunodeficiencies, hereditary anemias, and metabolic disorders.1,2 GT is a multi-step process encompassing the...
Open in Who Shared Issue with article?
See all 3 articles